

## Target Audience

Infectious disease/clinical microbiology/infection prevention & control, and public health professionals from low middle income countries (LMICs), dealing with the impact of the Covid-19 pandemic on healthcare systems.

## Faculty Members

**Seif Al-Abri**, Muscat, Oman  
**Benedetta Allegranzi**, Geneva, Switzerland  
**Adrian Brink**, Cape Town, South Africa  
**Vincent Cheng**, Hong Kong, China  
**Mauricio J. Farfan**, Santiago, Chile  
**Alex Friedrich**, Muenster, Germany  
**Brian Godman**, Glasgow, Scotland  
**Guido Granata**, Rome, Italy  
**Lorenzo Guizzaro**, Amsterdam, Netherlands  
**María Eugenia Gutiérrez Pimentel**, David, Panama  
**Ivan Fan Ngai Hung**, Hong Kong, China  
**Florian Lasch**, Amsterdam, Netherlands  
**Shaheen Mehtar**, Cape Town, South Africa  
**Eskild Petersen**, Aarhus, Denmark  
**Nicola Petrosillo**, Rome, Italy  
**Pilar Retamar**, Sevilla, Spain  
**Camilla Rodrigues**, Mumbai, India  
**Maurizio Sanguinetti**, Rome, Italy  
**Jeroen Schouten**, Nijmegen, Netherlands  
**Nusrat Shafiq**, Chandigarh, India  
**Evelina Tacconelli**, Verona, Italy  
**Juan Pablo Torres**, Santiago, Chile  
**Ramasubramanian Venkatasubramanian**, Chennai, India  
**Margreet Vos**, Rotterdam, Netherlands  
**Kamini Walia**, New Delhi, India  
**Sean Wasserman**, Cape Town, South Africa

## Organiser

- ESCMID International Affairs Subcommittee – EIAS

## Other Organisers

- EITaF, ESGNI, ESGAP, EUCIC, MJC IC UEMS

## Course Coordinators

**Nicola Petrosillo**, Rome, Italy  
**Adrian Brink**, Cape Town, South Africa

## Contact

### Contact Person (Scientific Programme)

#### Nicola Petrosillo

Foundation, University Hospital Campus Bio-medico  
Via Alvaro del Portillo 200 – 00128 Rome  
Italy

+39 06225418955

n.petrosillo@policlinicocampus.it  
nicola.petrosillo@escmid.org

#### Adrian J. Brink

Division of Medical Microbiology, Department of Pathology,  
Faculty of Health Sciences, University of Cape Town,  
Cape Town, South Africa  
Rondebosch, Cape Town, 7700  
South Africa

+27 021 406 6083

adrian.brink@uct.ac.za



© ESCMID, June 2022



## ESCMID Online Education Course

### COVID-19 collateral damage: impact on healthcare services in LMICs (Africa, Asia, South America)

Online  
20 – 21 October 2022



## ESCMID Online Education Course

### Organisation

#### Registration Procedure

Register on the ESCMID website at [www.escmid.org/education](http://www.escmid.org/education) by 2 October 2022.

#### Registration Fee

EUR 150 for ESCMID members  
EUR 200 for all others

For Young Scientist Members EUR 50  
For LMICs EUR 20

#### Course Objective

The current and future impact of the COVID-19 pandemic on the health-care systems is poorly understood. During the SARS-CoV-2 pandemic, numerous research studies and public health programs had been compromised substantially. All efforts and resources were directed to the fight against COVID-19. While this situation was equally important in European and North American countries, in LMICs from Asia, Africa, and South America, limited resources may have had a more substantial impact on health systems.

Notably, the re-direction and allocation of health resources to the care of patients with COVID-19, resulted in a decrease in the prevention, diagnosis, treatment and follow-up of patients with infectious diseases such as HIV, TB, malaria, etc. Ante-natal care and paediatric vaccination programs may also have been affected.

Moreover, infection prevention control (IPC) and antimicrobial stewardship programs (ASP) may have been affected due to the shortage of human resources and funding. In addition, the impact on antibiotic consumption in LMICs is mostly unknown. Several reports have highlighted the indiscriminate use of oral and intravenous antibiotics in LMICs, and the impact on antibiotic resistance is bound to be substantial.

The aim of the course is to update the audience on the collateral health-care damages caused by the COVID-19 pandemic, concerning prevention and management of infectious diseases, clinical microbiology, IPC and ASPs in LMICs, and to assess the barriers, facilitators and strategies for the normal resumption of non-COVID-19 healthcare activities.

# Course Programme

Session times are specified in Central European Summer Time (CEST) – UTC+2

Thursday, 20 October 2022

09:00 – 09:10 **Reception & Opening**

## 1. Impact of Covid-19 on public health and communicable diseases programmes

Moderators *Eskild Petersen, Seif Al-Abri*

### Learning outcomes

The COVID-19 pandemic has had both negative and positive impacts on infectious diseases of public health importance. Shifting public health resources to COVID-19 detection, control and prevention has negatively impacted, amongst others, on tuberculosis, malaria and sexually transmitted diseases control efforts. The audience will obtain knowledge to what extent control efforts have been affected in various parts of the world and what is required to negate the negative impact.

09:10 – 09:40 **Impact in Sub Saharan Africa**

*Sean Wasserman (South Africa)*

09:40 – 10:10 **Impact in India**

*Ramasubramanian Venkatasubramanian (India)*

10:10 – 10:40 **Impact in South/Central America**

*María Eugenia Gutiérrez Pimentel (Panama)*

10:40 – 11:00 **Q&A**

11:00 – 11:30 **Interactive session**

**The present and the future of the public health programmes and how to expedite “recovery”**

## 2. The impact of COVID-19 on non-essential research

Moderators *Alex Friedrich, Adrian Brink*

### Learning outcomes

Scientists across the globe had mobilized to combat COVID-19 but for those who could not redirect their efforts to COVID-19, non-Covid research was regarded as non-essential, and in most cases came to a standstill. Simultaneously, many clinical studies on diseases other than COVID-19 were halted in their tracks. The audience will learn to what extent this took place globally and what impact it had on clinical trials and implications thereof.

11:30 – 12:00 **The impact of COVID-19 on research worldwide: highlights and gloom**

*Nicola Petrosillo (Italy)*

12:00 – 12:30 **The non-COVID-19 clinical trials at the time of the pandemic**

*Lorenzo Guizzaro (Netherlands)  
Florian Lasch (Netherlands)*

12:30 – 12:40 **Q&A**

12:40 – 13:00 **Interactive session**

**Research: how and when will it go back as before COVID-19?**

13:00 – 14:00 **Lunch break**

## 3. Impact of Covid-19 on Infection Prevention & Control (IPC) interventions and initiatives

Moderators *Margreet Vos  
Ramasubramanian Venkatasubramanian*

### Learning outcomes

The COVID-19 pandemic has affected IPC programs worldwide and equally pertinent, resistance surveillance, and as a consequence, changes in healthcare-associated infection rates. In this session, the audience will learn not only of the impact in various regions of the world, but the current barriers, facilitators and strategies for the normal resumption of IPC and AMR surveillance.

14:00 – 14:30 **Impact on IPC in Sub Saharan Africa**

*Shaheen Mehtar (South Africa)*

14:30 – 15:00 **Impact on IPC in India**

*Camilla Rodrigues (India)*

15:00 – 15:30 **Impact on IPC in China**

*Ivan Fan Ngai Hung (China)*

15:30 – 16:00 **Impact on IPC in South/Central America**

*Juan Pablo Torres (Chile)*

16:00 – 16:30 **Impact on IPC in North Africa-Middle East**

*Seif Al-Abri (Oman)*

16:30 – 17:00 **Impact of the pandemic on the surveillance of antimicrobial resistance (AMR) in the healthcare settings globally**

*Pilar Retamar (Spain)*

17:00 – 17:15 **Q&A**

17:15 – 17:50 **Interactive session**

**COVID-19 vs IPC and AMR surveillance: what do we have to resume IPC and AMR surveillance and what strategies have worked or otherwise not**

17:50 **End of day**

Friday, 21 October 2022

09:15 – 09:30 **Welcome and overview of day two**

## 4. Antimicrobial consumption and resistance during COVID-19

Moderators *Jeroen Schouten, Camilla Rodrigues*

### Learning outcomes

The audience will learn how COVID-19 pandemic had fueled the ongoing antimicrobial resistance (AMR) global crisis due to the increase in the use of antibiotics to treat COVID-19 patients and disruptions to infection prevention and control practices in overwhelmed health systems. The session will also focus on reviving surveillance of consumption and AMR, to enable strategized interventions.

09:30 – 10:00 **Changes in antibiotic consumption and resistance in Sub Saharan Africa**

*Brian Godman (Scotland)*

10:00 – 10:30 **Changes in antibiotic consumption and resistance in India**

*Kamini Walia (India)*

10:30 – 11:00 **Changes in antibiotic consumption and resistance in China**

*Vincent Cheng (China)*

11:00 – 11:30 **Changes in antibiotic consumption and resistance in South/Central America**

*Mauricio J. Farfan (Chile)*

11:30 – 11:40 **Q&A**

11:40 – 12:10 **Interactive session**

**AMR in LMICs in the COVID-19 era: are we in time to intervene and how should we go about reducing consumption and minimize AMR spread?”**

12:10 – 13:10 **Lunch break**

## 5. Impact of Covid-19 on bacterial epidemiology

Moderators *Evelina Tacconelli, Mauricio Farfan*

### Learning outcomes

Whatever positive traction that was gained in combatting hospital-acquired infections during recent years may have been lost during the SARS-CoV-2 pandemic. The audience will learn what the collateral damage caused by Covid-19, had on global changes in bacterial epidemiology. Furthermore, the audience will be presented with strategies how to break down AMS and IPC silos, in light of increases in difficult-to-treat resistance.

13:10 – 13:40 **Global epidemiology of *Clostridioides difficile* infections during Covid-19**

*Guido Granata (Italy)*

13:40 – 14:10 **Global epidemiology of gram-negative bacteria during COVID-19**

*Adrian Brink (South Africa)*

14:10 – 14:40 **Global epidemiology of gram-positive bacteria during Covid-19**

*Maurizio Sanguinetti (Italy)*

14:40 – 15:10 **Antimicrobial stewardship programs: Competing COVID-19 priorities**

*Nusrat Shafiq (India)*

15:10 – 15:40 **Future direction: Strategies to overcome barriers and facilitators to negate Covid-19 impact**

*Benedetta Allegranzi (Switzerland)*

15:40 – 16:30 **Q&A**

16:30 – 17:00 **Interactive session  
ASPs, IPC and AMR: bridging the gap and breaking down silos**

17:00 – 17:30 **Conclusions and closure of the course**